- Home
- ENTG vs EXAS Comparison
ENTG vs EXAS Comparison
Compare ENTG & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTG
- EXAS
- Stock Information
- Founded
- ENTG 1966
- EXAS 1995
- Country
- ENTG United States
- EXAS United States
- Employees
- ENTG N/A
- EXAS N/A
- Industry
- ENTG Plastic Products
- EXAS Medical Specialities
- Sector
- ENTG Industrials
- EXAS Health Care
- Exchange
- ENTG Nasdaq
- EXAS Nasdaq
- Market Cap
- ENTG 13.9B
- EXAS 11.0B
- IPO Year
- ENTG 2000
- EXAS N/A
- Fundamental
- Price
- ENTG $85.73
- EXAS $65.83
- Analyst Decision
- ENTG Buy
- EXAS Strong Buy
- Analyst Count
- ENTG 11
- EXAS 21
- Target Price
- ENTG $107.09
- EXAS $71.86
- AVG Volume (30 Days)
- ENTG 2.3M
- EXAS 2.9M
- Earning Date
- ENTG 10-30-2025
- EXAS 11-03-2025
- Dividend Yield
- ENTG 0.46%
- EXAS N/A
- EPS Growth
- ENTG 26.59
- EXAS N/A
- EPS
- ENTG 1.90
- EXAS N/A
- Revenue
- ENTG $3,222,508,000.00
- EXAS $3,082,033,000.00
- Revenue This Year
- ENTG $0.33
- EXAS $16.68
- Revenue Next Year
- ENTG $6.33
- EXAS $12.36
- P/E Ratio
- ENTG $45.63
- EXAS N/A
- Revenue Growth
- ENTG 0.59
- EXAS 14.47
- 52 Week Low
- ENTG $60.75
- EXAS $38.81
- 52 Week High
- ENTG $112.36
- EXAS $72.81
- Technical
- Relative Strength Index (RSI)
- ENTG 43.89
- EXAS 61.04
- Support Level
- ENTG $86.14
- EXAS $62.39
- Resistance Level
- ENTG $90.47
- EXAS $72.81
- Average True Range (ATR)
- ENTG 3.94
- EXAS 2.11
- MACD
- ENTG -0.81
- EXAS -0.01
- Stochastic Oscillator
- ENTG 24.50
- EXAS 30.90
About ENTG Entegris Inc.
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.